Precigen (PGEN) Earnings Date & Reports

Key Takeaways

• Precigen is set to report second quarter 2026 financial results on August 4, 2026, after the U.S. market close. A conference call will follow at 4:30 PM ET.
• Consensus analyst estimates project Q2 EPS of -$0.01, a significant improvement from -$0.09 in the same quarter last year, on revenue of approximately $27.8 million to $28.3 million.
• PAPZIMEOS, the company's flagship gene therapy for recurrent respiratory papillomatosis (RRP), remains the central focus. The product generated $21.6 million in net revenue in Q1 2026 and management has signaled accelerating launch momentum heading into Q2.
• The company beat both revenue and EPS estimates in Q1 2026, reporting $23.25 million in total revenue versus the $20.8 million consensus and an EPS of -$0.02 against a -$0.03 forecast.
• Investors will closely monitor cash burn trends and any updates on management's target of reaching cash-flow breakeven by year-end 2026.

Earnings Context and Why It Matters

Precigen (NASDAQ: PGEN) enters its Q2 2026 earnings report at a pivotal moment. Less than a year into the commercial launch of PAPZIMEOS — the first FDA-approved therapy for adult recurrent respiratory papillomatosis — the company has transformed its revenue profile. Total revenue surged 1,634% year-over-year in Q1 2026, driven overwhelmingly by PAPZIMEOS sales. This quarter's results will test whether that momentum is sustainable. A permanent J-code for PAPZIMEOS took effect on April 1, 2026, which is expected to broaden access at major medical centers. Investors are watching to see whether the launch trajectory continues to accelerate as management has indicated, or whether early adoption enthusiasm begins to level off. The report also carries implications for Precigen's broader pipeline narrative and its path to profitability.

Earnings Expectations

Wall Street analysts have set the bar for Precigen's second quarter at a consensus EPS of -$0.01, a dramatic narrowing from the -$0.09 loss per share reported in Q2 2025. Revenue estimates range from approximately $27.8 million to $28.3 million, which would represent roughly a 3,200% increase from the $856,000 reported in the prior-year quarter — a reflection of the PAPZIMEOS launch effect that was barely underway this time last year. For context, in Q1 2026 PAPZIMEOS contributed $21.6 million in net product revenue, handily exceeding management's guidance floor of $18 million. H.C. Wainwright subsequently raised its full-year 2026 PAPZIMEOS sales estimate to $130 million. No formal Q2 revenue guidance has been issued, but management has described the launch trajectory as accelerating heading into the second quarter. Beyond the top and bottom line, key metrics to watch include gross margin expansion, operating expense trends — particularly selling, general, and administrative (SG&A) costs tied to commercialization — and the pace of cash consumption, which management expects to moderate from Q1 levels.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers an AI-powered stock and ETF discovery platform designed to streamline market research. The tool enables traders and investors to scan thousands of equities using customizable filters that span technical patterns, fundamental data, volatility metrics, industry classification, market capitalization, and proprietary AI-driven signals. Whether looking for breakout candidates, stocks exhibiting specific chart patterns, or names meeting strict valuation criteria, the screener surfaces actionable ideas far more efficiently than manual methods. In a market environment where timing and precision matter, leveraging an intelligent screening tool can help investors stay ahead of the curve.

Market Reaction and Investor Sentiment

Precigen shares have staged a remarkable rally over the past twelve months, climbing from a 52-week low of $1.54 to recent trading levels near $5.50 — a gain of over 250%. The stock currently carries a consensus analyst rating of Hold to Moderate Buy, with price targets ranging from $11.00 to $14.00, implying significant potential upside from current levels. Following the Q1 2026 earnings beat in May, shares rose more than 10%, reflecting investor enthusiasm for the PAPZIMEOS commercial story. Sentiment heading into Q2 results appears cautiously optimistic but tempered by concerns around elevated cash burn and a market capitalization near $2 billion that prices in substantial future growth. Insider selling activity — approximately $4.6 million over the past three months — adds a note of caution. The stock's elevated beta of 1.72 suggests above-average volatility around earnings, and any deviation from the accelerating revenue narrative could trigger outsized price swings.

Forward Outlook and Key Factors to Monitor

The August 4 report will likely set the tone for Precigen's second half of 2026. The most immediate factor to monitor is the PAPZIMEOS revenue trajectory. With a permanent J-code now in effect for a full quarter, investors should look for evidence that additional major medical centers have come on board and that the prescriber base is broadening beyond early adopters. Sequential revenue growth from Q1's $21.6 million will be a closely watched benchmark.

Cash management represents another critical theme. Precigen's path to cash-flow breakeven by the end of 2026 hinges on both revenue growth and expense discipline. In Q1, elevated SG&A spending tied to the commercial launch drew scrutiny. Management has signaled that cash consumption would moderate in Q2, and confirmation of that trend would likely be well received. The company's balance sheet shows approximately $56 million in cash against roughly $98 million in debt, making capital efficiency a priority.

Beyond the immediate quarter, the broader pipeline remains a longer-term catalyst. Updates on programs in immuno-oncology, autoimmune disorders, and infectious diseases — alongside any clinical data readouts — could shape the narrative around Precigen's value beyond PAPZIMEOS. Analysts currently project the company could generate full-year 2026 revenue of approximately $124 million and turn EPS-positive in future quarters, milestones that would mark a historic shift for a company that has long operated at a net loss. Whether those projections remain intact after the Q2 print will depend heavily on the durability of PAPZIMEOS demand signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations